{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:16:53Z","timestamp":1790781413534,"version":"4.1.0"},"reference-count":74,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T00:00:00Z","timestamp":1477440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009045","name":"Uniwersytet Jagiello\u0144ski Collegium Medicum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain and Behavior"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Chemotherapy\u2010induced neuropathies are one of the most common side effects of cancer treatment, surpassing bone marrow suppression and kidney dysfunction. Chemotherapy effects on the nervous system vary between different classes of drugs and depend on specific chemical and physical properties of the drug used. The three most neurotoxic classes of anti\u2010cancer drugs are: platinum\u2010based drugs, taxanes, and thalidomide and its analogs; other, less neurotoxic but also commonly used drugs are: bortezomib, ixabepilone, and vinca alkaloids.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Here, in this paper, based on our experience and current knowledge, we provide a short review of the most common, neuropathy\u2010inducing anti\u2010cancer drugs, describe the most prevalent neuropathy symptoms produced by each of them, and outline preventive measures and treatment guidelines for cancer patients suffering from neuropathy and for their health care providers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients should be encouraged to report any signs of neuropathic pain, alteration in sensory perception, tingling, numbness, burning, increased hot\/cold sensitivity and motor dysfunctions as early as possible. If known neurotoxic chemotherapeutics are used, a neurological examination with electrophysiological evaluation should be implemented early in the course of treatment so, both patients and physicians would be better prepared to cope with possible neurotoxic effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The use of neurotoxic chemotherapeutics should be closely monitored and if clinically permitted, that is, if a patient shows signs of cancer regression, drug doses should be reduced or combined with other less neurotoxic anti\u2010cancer medication. If not counteractive, the use of over the counter antineuropathic supplements such as calcium or magnesium might be encouraged. If physically possible, patients should also be encouraged to exercise regularly and avoid factors that might increase nerve damage such as excessive drinking, smoking, or sitting in a cramped position.<\/jats:p><\/jats:sec>","DOI":"10.1002\/brb3.558","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T04:06:39Z","timestamp":1477541199000},"source":"Crossref","is-referenced-by-count":176,"title":["Chemotherapy\u2010induced neuropathies\u2014a growing problem for patients and health care providers"],"prefix":"10.1002","volume":"7","author":[{"given":"Marta","family":"Banach","sequence":"first","affiliation":[{"name":"Department of Neurology Collegium Medicum Jagiellonian University  Krakow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judyta K.","family":"Juranek","sequence":"additional","affiliation":[{"name":"Department of Medicine New York University Langone Medical Center  New York NY USA"},{"name":"Department of Pathology Faculty of Medical Science University of Warmia and Mazury  Olsztyn Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta L.","family":"Zygulska","sequence":"additional","affiliation":[{"name":"Department of Oncology University Hospital Jagiellonian University  Krakow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,10,26]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568009033481967"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1516-31802013000100006"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1758"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27732"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-149385"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-006-0072-3"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0044"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23859"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.11.014"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000130499.91775.2C"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072995"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.11.012"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.061"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.62.12.2291"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2008.00193.x"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.2174\/156800911794519752"},{"key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archderm.1984.01650390060012","article-title":"Thalidomide neurotoxicity","volume":"120","author":"Clemmensen O. J.","year":"1984","journal-title":"Archives of Dermatology"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.07.022"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.1057497"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.11.052"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn093"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.0894"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.90"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139394"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-355"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-2075-1"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.8738"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.2943"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-005-0782-y"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.97"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP48729"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.0792"},{"key":"e_1_2_12_34_1","first-page":"2212","article-title":"Mechanism of inhibition of cell proliferation by Vinca alkaloids","volume":"51","author":"Jordan M. A.","year":"1991","journal-title":"Cancer Research"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1385\/1592590128"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.7.2101"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2306-7"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-1018-3"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2010.00271.x"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2008.03096.x"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-S505"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg301"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.2008.00996.x"},{"key":"e_1_2_12_44_1","first-page":"1805","article-title":"Pilot study of duloxetine for cancer patients with neuropathic pain non\u2010responsive to pregabalin","volume":"32","author":"Matsuoka H.","year":"2012","journal-title":"Anticancer Res"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0840"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxics3030294"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e32832a2dc1"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2013.03.009"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-010-0183-1"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/104345429501200310"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0772-03"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01999566"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d5279e"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124875"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-993"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.4.593"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000267271.18475.fe"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23008"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327480301000502"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/349653"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.2174\/157015906776359568"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.09.020"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-009-0586-0"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2807-5"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2813"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008211226339"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000077"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2013-000758"},{"key":"e_1_2_12_69_1","first-page":"1192","article-title":"Reduction of paclitaxel\u2010induced peripheral neuropathy with glutamine","volume":"7","author":"Vahdat L.","year":"2001","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1384-0"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2629-3"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1237-2"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-3-312"},{"key":"e_1_2_12_74_1","first-page":"231","article-title":"Lesions of the peripheral nerves: MR neurography as an innovative supplement to electrodiagnostics","volume":"42","author":"Wessig C.","year":"2011","journal-title":"Klinische Neurophysiologie"},{"key":"e_1_2_12_75_1","unstructured":"WHO(2014).The selection and use of essential medicines. World Health Organization technical report series:i\u2010xiv 1\u2010219 back cover."}],"container-title":["Brain and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbrb3.558","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbrb3.558","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T16:16:57Z","timestamp":1696609017000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/brb3.558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,26]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1002\/brb3.558"],"URL":"https:\/\/doi.org\/10.1002\/brb3.558","archive":["Portico"],"relation":{},"ISSN":["2162-3279","2162-3279"],"issn-type":[{"value":"2162-3279","type":"print"},{"value":"2162-3279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,26]]},"article-number":"e00558"}}